News

How Poor Blood Flow Influences Cancer Progression

How Poor Blood Flow Influences Cancer Progression

How Restricted Blood Flow Influences Cancer Growth

Recent research has uncovered a fascinating link between blood flow and cancer growth. New evidence suggests that restricted blood flow can prematurely age the immune system by weakening its defense against tumors. This study, conducted by experts from NYU Langone Health, reveals essential insights into how peripheral ischemia may enhance cancer aggressiveness.

The Role of Ischemia in Tumor Growth

Ischemia, characterized by reduced blood flow due to fatty deposits in artery walls, leads to inflammation and clotting, making it a significant health concern. It not only impacts circulation but has a profound effect on the body's ability to combat diseases, particularly cancer. In their study, researchers observed that when blood flow was restricted in the arteries of mice, the rate of breast tumor growth doubled compared to those without such restrictions.

Findings from the Study

The findings were published in the journal JACC-CardioOncology. The research suggests that the damaging effects of ischemia transcend beyond cardiovascular complications and may significantly impact cancer outcomes. When blood flow is impaired, the immune response is compromised, allowing cancer cells to thrive. The researchers assert that this poses essential questions regarding how to address both metabolic and vascular health in cancer care.

Understanding Immune System Changes

One of the most striking revelations from the research indicates that restricted blood flow induces a shift in immune cell populations within the body. These changes mirror the alterations seen in aging immune systems. The study's authors utilized a mouse model with breast tumors to simulate ischemia and observe tumor development. The results indicated that impaired blood flow favors the creation of certain immune cells that do not effectively respond to tumors.

Impact of Ischemia on Immune Responses

The immune system typically functions by ramping up responses to fight off infections and cancer, relying on a reservoir of stem cells in the bone marrow. However, the study highlighted how reduced blood flow causes a disruption in this balance, leading to an increase in immune-suppressive cells. These immune-suppressive cells, including specific types of macrophages and monocytes, accumulate in tumors, effectively shielding the cancer from immune attacks.

Long-term Consequences of Restricted Blood Flow

Another pivotal aspect of the study involves the long-lasting effects ischemia has on the immune system. Not only does it alter gene expression in immune cells, but it also reorganizes chromatin structures that control DNA accessibility, further inhibiting immune responses against cancers. The implications for cancer treatment are vast, prompting a reconsideration of how pre-existing vascular diseases might influence cancer severity.

Future Directions for Cancer Treatment

The insights gained from this research could spur new strategies for cancer prevention and treatment. There is a growing interest in developing therapies that can modulate inflammatory responses to counteract the adverse effects caused by ischemia. Additionally, the possibility of implementing earlier cancer screenings for patients suffering from peripheral artery disease may provide a proactive approach to improving cancer outcomes.

About NYU Langone Health

NYU Langone Health stands out for its commitment to delivering high-quality patient care, consistently ranking among the top medical centers. With an extensive focus on research, the institution is at the forefront of crafting innovative treatment strategies that not only improve immediate patient outcomes but also aim to redefine how we understand disease processes. Their comprehensive range of services spans across numerous facilities, echoing their dedication to community health and well-being.

Frequently Asked Questions

What is ischemia and how does it relate to cancer growth?

Ischemia is a condition characterized by reduced blood flow to tissues, which can compromise immune function and allow tumors to grow more rapidly.

How does restricted blood flow affect immune cell production?

Restricted blood flow leads to a shift in the production of immune cells toward those that suppress immune responses, reducing the body's ability to fight cancer.

Can this research change cancer treatment strategies?

Yes, the findings highlight the importance of considering vascular health in cancer treatments, potentially leading to new approaches in prevention and management.

What long-term effects does ischemia have on the immune system?

Ischemia can induce changes in gene expression and rearrangement of chromatin, which may weaken the immune response to tumors over time.

What potential future studies could emerge from this research?

Future studies may focus on evaluating inflammation-modulating therapies and their effectiveness in combating tumor growth in patients with restricted blood flow.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Infotech's 2026 Report Crowns PSA Software Leaders

Updated Category News Views 20

Spotlight on PSA Trailblazers It's 2026, and Infotech has dropped its latest bombshell—the Professional Services Automation Data Quadrant Report. This ain't just your run-of-the-mill software rankings; it's a peek into tools that could make or break project management for service-oriented businesses. Five top dogs, RocketLane, Wrike, Accelo, SAP Professional Services...

Continue Reading
NORROY's Radiopharma Innovations: EANM Highlights

Updated Category News Views 93

Breaking Ground: NORROY's Radiopharmaceutical Innovations If you thought the radiopharmaceutical game was stuck in the same ol' rut, NORROY Bioscience just flipped the script. Standing out at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26) in Vienna, they trotted out enough breakthroughs to make you wonder if they're secretly running on...

Continue Reading
AlphaESS Secures Fifth Tier 1 Status Amid Growth

Updated Category News Views 177

AlphaESS: Consistency Breeds Success Can't ignore a company that keeps hitting the marks quarter after quarter, kid. AlphaESS just bagged its fifth consecutive Tier 1 status from BloombergNEF for Q4 2026—that's no joke in the buzzing world of energy storage. What makes this outfit tick? It's not just sticking to the same old script; they keep leveling up while everyone...

Continue Reading
GomSpace Eyes SEK 1.6 Billion Revenue by 2030

Updated Category News Views 135

Cracking Open GomSpace's Q3 Gains You don't just stumble upon profitability in this market; that's for sure. GomSpace, however, seems to have a knack for finding its stride amidst the chaos. In their latest earnings report, it looks like they're not just coasting—they're powering through with profitable growth in the third quarter. Who would have thought? These folks...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 93

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
KT&G Soars with Record Profits, Aggressive Share Buybacks

Updated Category News Views 73

KT&G Climbs to New Heights with Record-Setting Q3 If you're eyeballing the markets like a hawk, KT&G (KRX: 033780) just gave you something to squawk about. In the world of stocks, milestones are few and far between, but KT&G is handing out milestones like candy in Q3. They rolled out their numbers for the quarter, and let me tell ya, this was no pie-in-the-sky nonsense....

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 73

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Magnolia Data Breach: Legal Stakes Loom for Seniors

Updated Category News Views 192

Elderly Residents at Risk After Data Breach Well, here we go again — another day, another data breach debacle. This time, it's Magnolia Management putting senior residents' sensitive information on a silver platter for potential cyber intruders. We're talking names, Social Security numbers, and medical records — the whole shebang. When you're handling such crucial...

Continue Reading
Multi-Society Panel Boosts Vaccine Guidance Clarity

Updated Category News Views 23

Vaccination Confusion: Could Clarity Finally Be Here? Here's the scoop, folks. In the swirling mess of immunization advice, a coalition of top medical societies has thrown a lifeline to clinicians. If you're drowning in conflicting vaccine guidance, this panel's unified stance might just be your life raft. The Coalition Forces of Immunization We have the Vaccine Guidance...

Continue Reading
Bram Schot Steers Marelli Through Chapter 11 Resurgence

Updated Category News Views 97

So, Marelli's rolling out the heavy artillery with the appointment of Bram Schot as their future Chair. This isn't just reshuffling a few chairs on the deck of a wobbly ship. No, Marelli's emergence from Chapter 11, with Schot at the helm, is more akin to a full-blown course correction. The man comes seasoned, having braved the corporate gales at Audi, Mercedes-Benz, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Boldyn Networks Achieves Major Player Status in Private 5G Market

Updated Category News Views 163

Boldyn Networks Achieves Major Recognition in Private 5G Sector Boldyn Networks, a global leader in private networks and shared communications infrastructure, has made waves in the telecommunications industry with its recent recognition as a Major Player in the IDC MarketScape: European Enterprise Private 5G Solutions 2025 Vendor Assessment. This validation reflects...

Continue Reading
LinkSquares Debuts All-Agentic CLM Platform for Legal Teams

Updated Category News Views 16

LinkSquares: A Game Changer for Contract Management In the world of legal and business operations, few things eat away at patience—let alone profits—like the cumbersome dance of contract management. Enter LinkSquares, strutting onto the stage with its new all-agentic CLM platform, promising to turn this often painful process into a streamlined operation that saves...

Continue Reading
Sanctuary Medicinals Triumphs at NECANN Cup with Recognition

Updated Category News Views 216

Sanctuary Medicinals Shines at NECANN Cup Boston 2025 Sanctuary Medicinals proudly celebrates a remarkable achievement at the 6th Annual NECANN Cup Boston. The company earned the impressive title of 4th place in the competitive Solvent Concentrates category. This accolade showcases Sanctuary Medicinals' unwavering commitment to excellence, innovation, and quality within...

Continue Reading
Patients Continue Obesity Treatments as Coverage Shrinks

Updated Category News Views 174

The Growing Challenge of Obesity Drug Coverage For many individuals battling obesity, the struggle is not just about losing weight. It’s also about bearing the financial burden of treatments. With increasing limitations from insurers regarding weight-loss drugs, patients are often forced to alter their lifestyles significantly. Vacations are postponed, dining out is...

Continue Reading
Humacyte, Inc. Investors Urged to Act Before Class Action Deadline

Updated Category News Views 123

Important Attention for Humacyte, Inc. Investors As an investor in Humacyte, Inc., it’s essential to stay informed about legal opportunities that could impact your investments. The Rosen Law Firm, known for its dedication to protecting investor rights, is reminding those who purchased Humacyte securities during a specified period about an important upcoming deadline....

Continue Reading